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Abstract
Pathogenicity was reportedly restored to an avirulent molecular clone of equine infectious anemia virus (EIAV) by substitution of 3
sequences from the pathogenic variant strain (EIAVPV). However, the incidence of disease in horses/ponies was found to be significantly
lower (P  0.016) with the chimeric clone (EIAVUK) than with EIAVPV. This was attributable to 3 rather than 5 regions of the proviral
genome, where EIAVUK differs from the consensus EIAVPV sequence by having a 68-bp duplication in the 3 LTR and arginine (R103)
rather than tryptophan (W103) at position 103 in the second exon of rev. In EIAVUK recipients the duplication was rapidly eliminated and
R103 replaced by W103 in the viral population. Furthermore, removal of the 3 variant sequences from EIAVUK (EIAVUK3) resulted in an
equivalent (P  0.013) disease potential in Equus caballus to EIAVPV. The 68-bp duplication and/or R103 may limit peak viral RNA
accumulation during acute infection.
© 2003 Elsevier Science (USA). All rights reserved.
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Introduction
Infectious molecular clones of equine infectious anemia
virus (EIAV) are potentially extremely valuable for identi-
fying the genetic elements responsible for pathogenicity in
this lentivirus. It was previously reported that virulence in
Equus caballus was conferred on a nonpathogenic infec-
tious molecular clone of EIAV by substitution of 3
sequences derived from the pathogenic variant strain
(EIAVPV). The resultant chimeric molecular clone was des-
ignated EIAVUK (Cook et al., 1998) and was initially ob-
served to produce signs of acute equine infectious anemia
(EIA) in three of four horse/pony recipients by 12 days
postinfection (dpi). These clinical signs consisted of a tran-
sient high fever (39°C) and thrombocytopenia, although
this lacked the severity required to interfere with blood-
clotting ability (Cook et al., 1998).
A fundamental property of the acute disease induced by
EIAVPV in E. caballus is that it is non-life-threatening and
invariably resolved within 1 to 3 days. If severe clinical
signs occur as a result of infection with this virus, they are
confined to the subsequent chronic stage of the disease
(Issel et al., 1992; Wang et al., 1994; Hammond et al.,
1997). This contrasts with EIAVWYOMING (EIAVWY) infec-
tions of horses or ponies. Although this viral strain is the
progenitor of EIAVPV (Malmquist et al., 1973; Orrego et al.,
1982; Rwambo et al., 1990) it often produces a very severe,
fatal form of acute EIA (Kemeny et al., 1971; Issel, unpub-
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lished data). Therefore, EIAVPV and EIAVWY occupy dif-
ferent areas in the broad spectrum of acute disease potential
observed with this lentivirus (Montelaro et al., 1993; Sellon
et al., 1994; Cook et al., 1996). As a result of the initial
observations, EIAVUK was interpreted as being directly
equivalent to EIAVPV (Cook et al., 1998) and was assumed
to contain the genetic determinants responsible for causing
episodes of moderate acute EIA. Furthermore, by compar-
ison (Cook et al., 1998) with other viral strains, including a
consensus sequence for 3 regions of the EIAVPV genome
(Lichtenstein et al., 1996; Leroux et al., 1997), these deter-
minants were mapped to transcription factor binding motifs
within the LTR and/or to specific env gene sequences,
including some in open reading frame (ORF) S3 (encoding
the second exon of rev). However, this conclusion was
challenged by a subsequent study in which 3 EIAVUK pony
recipients showed no overt clinical signs during a 180-day
observation period (Feng Li et al., 2000). Consequently,
EIAVUK was calculated to have a disease induction rate of
43% (3 of 7 recipients) compared to 87% seen in a survey
(Cook et al., 1998) of 23 (20 of 23 recipients) EIAVPV-
infected horses and ponies. Application of the Pearson 2
test to these results produced strong evidence for a signifi-
cant (P  0.016) difference between EIAVPV and EIAVUK
in the ability to rapidly induce acute EIA in populations of
E. caballus.
It was hypothesized that this difference in pathogenic-
ity could be the result of genetic variation between EIA-
VUK and the predominant members of the EIAVPV pop-
ulation, as represented by the consensus nucleotide
sequence. Previous analysis had demonstrated that EIA-
VUK differed at two locations from the consensus se-
quence for 3 regions of the EIAVPV genome (Lichten-
stein et al., 1996; Leroux et al., 1997). These consisted of
an unusual 68-bp duplication in the U3 region of the 3
LTR and the presence of arginine (R103) rather than
tryptophan (W103) at amino acid position 103 in ORF S3
(Cook et al., 1998). In addition to these previously iden-
tified differences it was noted that only 40% of the
EIAVUK genome was derived from EIAVPV, while the
remaining 60% was from the original avirulent molecular
clone (Cook et al., 1998). As gag and much of the
EIAVPV pol gene have not been sequenced it was con-
sidered feasible that biologically significant variation
might exist in these regions of the viral genome com-
pared with EIAVUK.
In this report evidence for consistent nonsynonymous
nucleotide differences in gag/pol between EIAVUK and
EIAVPV is presented, although this did not correlate with
pathogenicity. Instead the variation in disease potential
was found to map to 3 regions of the viral genome. In
EIAVUK-infected animals the 68-bp duplication in the
LTR was rapidly deleted from the viral population and
R103 was replaced by W103. Furthermore, viruses from a
variant of EIAVUK (EIAVUK3) that lacked the 68-bp
duplication and possessed W103 induced transient, mod-
erate acute febrile episodes in seven of eight recipients.
Results
Plasma-associated viral RNA levels following infection
with EIAVUK
Highly pathogenic strains of EIAV are expected to in-
duce clinical signs within 42 days of infection in at least 80
to 90% of horse/pony recipients. However, as previously
reported (Cook et al., 1998; Feng Li et al., 2000), the
appearance of clinical signs within this time frame was only
observed in three of seven EIAVUK-infected animals. In
Figs. 2A and B the plasma-associated viral RNA load in all
EIAVUK recipients during the period of acute viral replica-
tion is shown in the context of temperature profile and
platelet concentration. As expected the febrile episodes in
horses 614, 700, and 764 were associated with high viral
RNA burdens, although the amounts varied by almost 10-
fold from 1.44  107 copies/ml in 700 to 1.05 to 108
copies/ml in 764 (Fig. 2A). Furthermore, there was not an
absolute correlation between the level of viral RNA and
pyrexia. For example, the body temperatures of horses
94-14 and 94-20 remained well within the normal range for
E. caballus considering that both animals had viral RNA
Fig. 1. Organization of the EIAV proviral genome showing the relative positions of the 1/4861 oligonucleotide primer pair used in the production of the
EIAVPV4.9 molecular clones along with the location of the restriction endonuclease sites involved in the construction of EIAVUK2 (AspI–NcoI) and EIAVUK3
(BstXI–EcoRI). Position numbers are based on EIAVUK (GenBank Accession No. AFO16316) EcoRI is located immediately downstream of the 3 LTR.
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loads very similar to those detected in horse 700 during a
period of pronounced fever (39.4 °C, Figs. 2A and B). In
addition, the body temperature of horse 700 did not remain
elevated despite the fact that viral RNA levels at 15 and 21
dpi either exceeded or were similar to those measured dur-
ing the pyrexia episode at 12 dpi (Fig. 2A).
The viral RNA load data also suggested that some
animals could control initial EIAVUK replication more
effectively than others. This was particularly evident
between 94-17, which remained asymptomatic, and 764
(Figs. 2A and B). Interestingly, 764 not only had the
highest viral RNA burden associated with acute disease
of all EIAVUK-infected animals but was the only recipi-
ent of this virus to experience additional febrile episodes
that eventually became severe enough to require eutha-
nization (Cook et al., 1998).
Fig. 2. Clinical profiles of horses/ponies monitored during the early stages of EIAVUK infection for those animals that became febrile (A) and those that
remained afebrile (B). The rectal temperature (solid line) and platelet level (dotted line) expressed as platelets per microliter of whole blood are shown in
conjunction with the plasma-associated viral RNA burden (log10/ml, hatched bars) as determined by a multiplex real-time RT–PCR assay.
590 R.F. Cook et al. / Virology 313 (2003) 588–603
Analysis of EIAVPV gag-pol sequences
Most of the 5 region in the EIAVPV genome has not
been characterized. Therefore, DNA from EIAVPV-infected
cells was amplified by PCR using the 1-4861 oligonucleo-
tide primer pair (Fig. 1, Table 1 ) and molecularly cloned
into the pLG330/30 plasmid vector and four of the resultant
clones (EIAVPV4.9 a–d) were subjected to nucleotide se-
quence analysis. All of the EIAVPV4.9 clones tested were
identical to EIAVUK in the gag gene regions encoding the
matrix, core, and nucleocapsid proteins (Fig. 3A). However,
they differed from EIAVUK in having the codon for histi-
dine instead of an asparagine residue at amino acid position
45 in the carboxyl terminal domain of the P9 protein (Fig.
3A). In addition, one EIAVPV4.9 clone (d) encoded a proline
instead of a leucine residue at amino acid position 44 in P9
(Fig. 3A).
Analysis of pol gene sequences to the NcoI restriction
endonuclease at nucleotide position 4873 demonstrated
that the majority of differences between EIAVPV4.9 and
EIAVUK were located in the region encoding reverse
transcriptase (RT). Each EIAVPV4.9 clone contained
codons for valine instead of methionine at position 189,
arginine instead of leucine at position 196, and valine
instead of isoleucine at position 271 (Fig. 3B). Further-
more, three clones (a, c, and d) differed from the RT of
EIAVUK at the codon for amino acid position 425 (lysine
instead of arginine) and two of the clones (b and c) varied
at position 293 (isoleucine instead of valine). Some mi-
nor variation in RT between EIAVUK and individual
EIAVPV4.9 clones was also observed (Fig. 3B). Nonsyn-
onymous nucleotide sequence differences with EIAVUK
in regions encoding protease, dUTPase (DU), and the
amino terminal region of integrase were not conserved
between individual EIAVP4.9 clones (Fig. 3B). Complete
homology between EIAVUK and consensus EIAVPV se-
quences has been previously demonstrated for the re-
maining section of the pol gene encoding the carboxyl
terminal domain of integrase (Lichtenstein et al., 1996;
Leroux et al., 1997; Cook et al., 1998).
Substitution of EIAVPV4.9 sequences in EIAVUK and
infection of ponies with the resultant chimeric viruses
The nucleotide sequence analysis described above sug-
gested the existence of consistent potential amino acid dif-
ferences between EIAVUK and the majority of the EIAVPV
population in gag p9 and RT. As three of the EIAVPV4.9
molecular clones (b, c, and d) had minor inconsistent vari-
ations in regions of the pol gene outside RT, EIAVPV4.9A
was selected for the subsequent work culminating in animal
trials. A 4.23-kbp fragment derived by AspI–NcoI restric-
tion endonuclease digestion of EIAVPV4.9A (Fig. 1) was
substituted for equivalent sequences in EIAVUK and the
resultant chimeric molecular clone, designated EIAVUK2,
transfected into fetal equine kidney (FEK) cells. Following
titration in FEK cells, viruses derived from EIAVUK2 were
used to inoculate two ponies (873 and 930) at a dose of 4 
106 TCID50. These animals became infected, as evidenced
by seroconversion to EIAV antigens in the CELISA, but
neither showed signs of a febrile response during a 42-day
observation period (Fig. 4). Although only two animals
were infected, this experiment suggests that either
EIAVPV4.9A was not the optimum donor for gag/pol se-
quences (possibly because of the additional variation in RT
compared to the other EIAVPV4.9 clones examined, Fig. 3B)
or that the pathogenic potential of EIAVUK was reduced by
differences from EIAVPV in 3 rather than 5 regions of the
proviral genome.
Stability of the 68-bp duplication in the EIAVUK LTR in
vivo
If the 68-bp duplication in the 3 LTR of EIAVUK and/or
the possession of R103 instead of W103 were detrimental to
viral replication it is predicted, they would be exposed to
strong selective pressure in vivo.
To test the stability of the 68-bp duplication in vivo viral
RNA samples were isolated from the plasma of three
EIAVUK-infected horses/ponies that developed acute EIA
within 42 dpi (614, 700, and 764) and three (613, 94-14, and
94-20) that did not (Cook et al., 1998; Feng Li et al., 2000).
A region encompassing this duplication in these samples
Table 1
Oligonucleotide primers used in PCR and RT–PCR amplification of EIAV sequences.
Designation Positiona Sequence 5-3
HindIII/EIAV1 1–34 gactccaagcttTGTGGGGTTTTTATGAGGGGTTTTATAAATGATT
EIAV4861 4891–4861 ATAAATACTTCCCATGGTGTCTGTCCTCCC
EIAV7034 7034–7064 CTTCATGGAGCTAGGAACAATTTGGCACAA
EIAV7812 7812–7844 TTGATTATATTGGAAGAGCTTTAAATCCCTGGCA
EIAV8179 8209–8179 CCAGCAGAGAAGGGACTCAGACCGCAGAAT
XbaI/EIAV8283 8283–8250 gctctagaTGTAGGATCTCGAACAGACAAACTAGAGACAGGG
a Position numbers are based on the nucleotide sequence of EIAVUK GenBank Accession No. AFO16316. EIAV sequences are in uppercase, with
additional sequences in lowercase. The HindIII and XbaI restriction endonuclease sites are underlined.
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Fig. 3. Comparison of the deduced amino acid sequences encoded by EIAVUK (UK) with those in four (PVa, PVb, PVc, PVd) molecularly cloned 5 4.9-kbp
fragments derived from EIAVPV (EIAVPV4.9). The comparisons shown are for the entire open reading frame of gag (p15, p26, p11, p9) and for the open
reading frame of pol (preprotease, protease reverse transcriptase including RNase H, dUTPase, and amino terminal regions of integrase) to the NcoI restriction
endonuclease site at nucleotide position 4873 in EIAVUK.
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was amplified by RT–PCR using the oligonucleotide primer
pair 7812/8179 (Table 1). This primer pair was designed to
produce a 398-bp fragment with RNA containing the re-
peated element and a 330-bp fragment with samples having
a 3 U3 region of the standard size. DNA products having
these predicted sizes were generated using the 7812/8179
primer pair in RT–PCR amplification of RNA isolated from
EIAVUK and EIAVPV virions, respectively (Fig. 5). The
earliest time point at which products were reliably detected
in EIAVUK recipients following RT–PCR with 7812/8179
was 7 dpi. In all cases at this time, a fragment was produced
that comigrated with an equivalent product generated from
the EIAVUK virus stock (Fig. 5). Although this was exactly
as predicted it was something of a surprise to find a second
amplified product comigrating with the fragment produced
from 7812/8179 RT–PCR of EIAVPV virions (Fig. 5). Fur-
thermore, as the infection progressed the relative intensity
of the lower molecular weight fragment appeared to in-
crease, until by 21 dpi it was the only detectable product
(Fig. 5). The relative amounts of the two RT–PCR products
was estimated in the six EIAVUK recipients using an IS-
1000 Digital Imaging System (Alpha Innotech Corp., San
Leardo, CA), with the effects of DNA fragment size on
ethidium bromide binding corrected by multiplying the flu-
orescent intensity of the smaller product by a factor of
398/390. This demonstrated that at 7 dpi the smaller frag-
ment comprised between 43 and 64% of the total 7812/8179
RT–PCR product and that by 12 dpi this had increased to
between 72 and 89%. These results suggested that viruses
derived from EIAVUK were subject to strong selective pres-
sure in vivo resulting in replacement of the original infec-
tion population by a variant containing at least one deletion
in the 3 terminal region of the genome. To locate potential
deletions the 7812/8179 RT–PCR fragments generated us-
ing samples harvested at 8 and 12 dpi from four EIAVUK
recipients were molecularly cloned and subjected to nucle-
otide sequencing. For this analysis, 5 upper and 5 lower
fragment molecular clones from each animal at both time
points were examined. Therefore, in total representatives
from 40 higher molecular weight and 40 lower molecular
weight fragments were sequenced.
In each case the larger RT–PCR fragment was found to
contain an intact 68-bp duplication, whereas the LTR se-
quences in the smaller fragment were identical to the con-
sensus for EIAVPV (Lichtenstein et al., 1996; Leroux et al.,
1997). Therefore in horses/ponies EIAVUK is replaced by a
Fig. 4. Clinical profiles showing rectal temperature (solid line) and platelet
level (dotted line) expressed as platelets per microliter of whole blood for
two ponies (873, 930) infected with EIAVUK2.
Fig. 5. Size polymorphism within 3 terminal regions of viral RNA present in EIAVUK recipients. Viral RNA was extracted from plasma at various times
postinfection (D, dpi) and amplified using the RT–PCR primer pair 7812/8179, and the resultant products were visualized by electrophoresis followed by
ethidium bromide staining. The migrational characteristics of these RT–PCR products were compared to those fragments amplified under equivalent
conditions from EIAVUK (UK) and EIAVPV (PV) viral RNA. EIAVUK virions have a 68-bp duplication in their 3 LTR that is not present in the predominant
members of the EIAVPV population (Lichtenstein et al., 1996; Leroux et al., 1997; Cook et al., 1998). Only 94-14 and 764 are shown, as similar results were
obtained for all animals tested.
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viral population from which the 68-bp duplication has been
deleted in a precise and consistent manner.
Identity of the amino acid residue at position 103 in ORF
S3 in EIAVUK-infected animals
Following observations showing that the 68-bp duplica-
tion was unstable, studies were initiated to determine if the
codon for the arginine residue at amino acid position 103 in
ORF S3 of EIAVUK was maintained or replaced in vivo.
Viral RNA from the cell culture-derived stock of EIAVUK
or plasma from animals infected (613, 614, 700, 764, 94-14,
and 94-20) with this virus was amplified by RT–PCR using
the 7034/8179 oligonucleotide primer pair (Table 1). The
resultant 1107-bp product was molecularly cloned into the
pT7 Blue 3 plasmid vector and subjected to nucleotide
sequence analysis using previously described oligonucleo-
tide primers (Leroux et al., 1997). For each RNA sample a
minimum for four individual molecular clones were ana-
lyzed to determine the potential identity of the residue at
amino acid position 103 in ORF S3. In each clone se-
quenced from the cell culture-derived viral stocks of
EIAVUK this residue was deduced to be arginine, just as in
the original molecular clone (Table 2). The next samples
analyzed were from plasma harvested during febrile epi-
sodes. In horses 700 and 764, which had fever at 12 dpi
(Cook et al. 1998), all clones examined possessed the orig-
inal arginine at position 103. However, in pony 614, which
also had fever at 12 dpi (Cook et al. 1998), 22% of the
clones possessed tryptophan at this position (Table 2). Fur-
thermore, in samples from horse 764 taken during a subse-
quent, very severe febrile episode at 55 dpi (Cook et al.
1998) all of the clones tested had arginine replaced by
tryptophan (Table 2). The final phase of this analysis was
conducted on animals that did not experience disease during
the period of observation. In clones from 94-14 and 94-20 at
31, 46, or 82 dpi, a tryptophan residue was invariably
present at position 103 in ORF S3.
Infection of horses/ponies with viruses derived from
EIAVUK3
The rapid, selective changes in the EIAVUK population
observed in infected horses or ponies suggested that viruses
derived directly from this molecular clone were not optimal
in terms of replicative efficiency in vivo. Therefore,
EIAVUK was modified by removal of the 68-bp duplication
and by replacement of arginine at position 103 in ORF S3
by tryptophan. This was accomplished by substitution of a
BstXI/EcoRI fragment (Fig. 1) from an EIAVPV3.3 molec-
ular clone (Cook et al. 1998) that lacked these atypical
features and was, within this particular region, homologous
to the consensus sequence for EIAVPV (Lichtenstein et al.
1996; Leroux et al. 1997). The modified molecular clone
was designated EIAVUK3 and viruses derived from it were
used to infect 10 horses/ponies at a dose of 4 106 TCID50.
However, 2 of these animals were observed to have preex-
isting thrombocytopenia and although both experienced fe-
brile episodes they were excluded from further analysis. In
all of the remaining animals, infection was associated with
a decline in platelet numbers that ranged from 16 to 68%,
with a geometric mean of 37% (Figs. 4A and B). More
importantly, with the exception of horse 9 all EIAVUK3
recipients had at least one febrile episode (39°C) that
occurred between 9 and 13 dpi (Fig. 6).
Serological responses to infection with EIAVUK3 were
examined using a commercially available ELISA (Vira-
CHEK/EIA). In this test horses 662, 839, 6, and 10 were
seropositive to the p26 core antigen by 14 dpi, while 985,
986, 1, and 9 seroconverted by 21 dpi.
The amount of infectious virus present in plasma col-
lected at the time of maximum febrile response was deter-
mined by titration on FEK cells. In each case a rectal
temperature of  39°C was associated with a plasma vire-
mia level of at least 105 TCID50/ml. A more detailed picture
of the early pattern of EIAVUK3 replication was provided by
the analysis of plasma-associated viral RNA levels (Fig. 6).
In general the profile of viral RNA accumulation was sim-
ilar to that in EIAVUK recipients, with maximal burdens
occurring between 10 and 14 dpi. However, the peak levels
detected following infection with EIAVUK3 appeared to be
somewhat higher than those with EIAVUK (Fig. 6).
Statistical analysis of EIAVUK and EIAVUK3 infection
experiments in vivo
Analysis of the clinical data from these experiments by
the Pearson 2 test provided at least some evidence for the
hypothesis that the incidence of disease in the EIAVUK3-
infected group was significantly (P  0.067) higher than
Table 2
Identity of the amino acid residue at position 103 in ORF S3 in
EIAVUK recipients
Sample dpi R103 W103
EIAVUKa — 4 0
614b 12 7 2
700b 12 6 0
764b 12 5 0
764b 55 0 6
94-14c 31 0 4
94-14c 46 0 4
94-14c 82 0 5
94-20c 82 0 4
RNA isolated from plasma was amplified by RT–PCR using the oligo-
nucleotide primer pair EIAV7034/8179, molecularly cloned into the pT7 Blue
3 vector, and the amino acid at position 103 in ORFNS3 deduced from the
nucleotide sequence. A minimum of four individual molecular clones were
sequenced from each time point designated as days postinfection (dpi). The
single letter code is used to denote the amino acid residue present.
a Cell culture-derived stock from EIAVUK.
b Sample collected during a febrile episode.
c EIAVUK recipients that remained afebrile.
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that in animals receiving EIAVUK. However, there was
more rigorous support based on an analysis of the real-time
RT–PCR data by the T test for the occurrence of significant
differences (P  0.02) between EIAVUK- and EIAVUK3-
infected groups in peak plasma-associated viral RNA levels.
It was calculated that on average the peak viral RNA load in
the EIAVUK3-infected subjects was 1.72  108 copies/ml,
whereas on average that in the EIAVUK recipients was 2.85
Fig. 6. Clinical profiles of horses/ponies monitored during the early stages of EIAVUK3 infection. The rectal temperature (solid line) and platelet level (dotted
line) expressed as platelets per microliter of whole blood are shown in conjunction with the plasma-associated viral RNA burden (log10/ml, hatched bars)
as determined by a multiplex real-time RT–PCR assay.
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 107 copies/ml. In addition a linear regression model was
developed to evaluate dpi and the identity of the molecular
clone as factors involved in predicting viral RNA copy
number. The model, in which a log transformation was used
on both dpi and the number of copies, was a good fit (P 
0.0001) and indicated that both dpi and the type of molec-
ular clone (EIAVUK or EIAVUK3) were significant in pre-
dicting the number of plasma-associated viral RNA mole-
cules (P  0.0001 and P  0.0067, respectively).
Comparison of EIAVUK and EIAVUK3 in equine monocyte-
derived macrophage (MDM) and FEK cell cultures
To investigate if EIAVUK3 replicated to higher titers than
EIAVUK in vitro, viruses from each of the two molecular
clones were used to infect eight equine MDM cultures at a
m.o.i. of 0.1 TCID50. The cytopathic effect progressed at
equivalent rates and with both viruses and was 95% com-
plete by 6 dpi. At this time point amounts of viral RNA
present in the cell culture fluids were determined because
previous studies (Raabe et al., 1998; Cook, unpublished
data) using similar levels of infectivity have shown that this
corresponds with the maximum detectable yield of progeny
virions. Application of the T test to the final results dem-
onstrated there were no significant differences (P  0.44)
between EIAVUK (mean, 7.55  108 viral RNA copies/ml,
SD, 2.57) and EIAVUK3 (mean, 8.68  108 viral RNA
copies/ml, SD, 3.10). Similarly, analysis of the viral RNA
copy from a minimum of four independently transfected
FEK cell cultures for each molecular clone produced no
evidence for statistically significant differences (P  0.618)
in peak levels of accumulation between these viruses
(EIAVUK mean, 4.75  1010 viral RNA copies/ml, SD,
2.90; EIAVUK3 mean, 3.64  1010 viral RNA copies/ml,
SD, 3.36), confirming earlier studies in which viral yields
from EIAVUK- and EIAVUK3-infected macrophage and
FEK cultures were determined by titration in FEK cells.
Comparison of the EIAVUK and EIAVUK3 LTRs in a
reporter gene assay
Potential transcriptional effects of the 68-bp duplication
were investigated by comparing the activities of the
EIAVUK and EIAVUK3 LTRs in a chloramphenicol acetyl-
transferase (CAT) reporter gene assay. An intact copy of the
3 LTR from each infectious molecular clone was amplified
by PCR and ligated into the pCAT-basic vector to generate
pUKLTR-CAT and pUK3LTR-CAT. Plasmid DNA from
two separate preparations (a1,b1,a2,b2—Table 3A ) of each
LTR-CAT clone were transfected in triplicate into equine
dermal (ED) cells in conjunction with the EIAV tat protein
expression vector pRS-ETAT-M (Dorn et al., 1990). As a
control a single plasmid preparation was made in which
pUKLTR-CAT (a1) and pUK3LTR-CAT (a2) were cotrans-
fected in triplicate in ED cells with an expression vector
(pCI) that lacked any form of insert. In the presence of the
tat expression vector there were no significant differences
(P  0.403) between the LTR constructs in amounts of
CAT produced (Table 3A). As expected, only residual
amounts (0.3%) of CAT were detectable in pUK3LTR-
CAT-transfected cells when tat was absent. However, the
68-bp duplication in the EIAVUK LTR resulted in increased
basal transcriptional activity that was 20% of that observed
in the presence of tat. To ensure that this result was not
associated with a particular plasmid DNA preparation, three
independent plasmid preparations of pUKLTR-CAT
(b1,c1,d1) and pUK3LTR-CAT (b2,c2,d2) were each trans-
fected in triplicate into ED cells. Analysis of CAT produc-
tion in these cell cultures confirmed that basal, tat-indepen-
dent transcription from the LTR of EIAVUK was
significantly (P  0.0001) higher than that from EIAVUK3
(Table 3B).
Discussion
A comparison between the genomes of EIAVUK and
EIAVPV revealed a number of sequences that could be
responsible for the significant differences (P  0.016) be-
Table 3
Expression from the 3 LTR of EIAVUK and EIAVUK3 in the presence
and the absence of the EIAV tat protein
Sample OD405 nm
(mean  SD)
A
pUK LTR-CAT a1  tat 1.29  0.26
pUK LTR-CAT b1  tat 1.45  0.22
pUK3 LTR-CAT a2  tat 1.43  0.30
pUK3 LTR-CAT b2  tat 1.49  0.20
pUK LTR-CAT a1 0.276  0.10
pUK3 LTR-CAT a2 0.004  0.003
ED lysate 0.008 0.001
B
pUK LTR-CAT b1 0.327  0.05
pUK LTR-CAT c1 0.310  0.049
pUK LTR-CAT d1 0.287  0.103
pUK3 LTR-CAT b2 0.033  0.013
pUK3 LTR-CAT c2 0.007  0.004
pUK3 LTR-CAT d2 0.012  0.005
ED lysate 0.005 0.003
(A) Equine dermal (ED) cells were transfected with two independently
prepared plasmid preparations of pUKLTR-CAT (a1,b1) and pUK3LTR-
CAT (a2,b2) along with the EIAV tat expression plasmid pRS-ETAT-M.
Relative amounts of CAT expression were measured using a CAT-ELISA
with the optical density determined at 405 nm (OD405nm). As an additional
control to untransfected cells (ED lysate) one preparation (a1,a2) of each
LTR-CAT reporter gene construct was transfected with pCI in place of
pRS-ETAT-M. The results from three separate transfection experiments for
each plasmid preparation are presented as the mean OD405nm  standard
deviation (SD). (B) As a consequence of the first experiments, ED cells
were transfected using three independent preparations of pUKLTR-CAT
(b1,c1,d1) and pUK3LTR-CAT (b2,c2,d2) without pRS-ETAT-M. The re-
sults of the CAT expression from three separate transfection experiments
for each plasmid preparation are shown as the mean OD405nm (SD).
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tween those viruses in the ability to rapidly induce acute
EIA in populations of E. caballus. Evidence for consistent
nonsynonymous nucleotide differences between EIAVUK
and EIAVPV in the gag p9 protein and in the 51-kDa subunit
(DeVico et al., 1991; Wohrl et al., 1994) of reverse tran-
scriptase was provided by nucleotide sequencing of four
EIAVPV4.9 molecular clones. As gag p9 is essential for the
release of nascent viral particles from the host cell plasma
membrane (Puffer et al., 1997; Chen et al., 2001; Li et al.,
2002) and as reverse transcriptase produces complementary
viral DNA from genomic RNA, variation in either of these
key structural components could have a significant impact
on viral replication. However, the accumulated evidence
argues against potential variation in gag/pol being the main
contributing factor to the difference in pathogenicity be-
tween EIAVUK and EIAVPV. Signs of acute disease were
not observed in either of the two ponies infected with a
variant of EIAVUK (EIAVUK2) containing gag/pol se-
quences from EIAV4.9A. In addition, EIAVUK3, whose gag/
pol sequences were unaltered from EIAVUK, produced a
similar (P  0.03) incidence of acute EIA to EIAVPV in
populations of E. caballus and finally, early clinical signs
were induced in two of two ponies infected with a variant
(EIAVUK4) of EIAVUK2 (produced by substitution of the
3 3.3-kbp NcoI/EcoRI fragment shown in Fig. 1 from
EIAVUK3) containing 3 sequences derived from EIAVUK3
(R.F. Cook, unpublished data). It therefore appears that
variation between EIAVUK and EIAVPV in gag/pol is re-
stricted to highly conservative amino acid substitutions
and/or is located within domains not connected with deter-
minants of virulence. Support for the notion of conservative
substitutions is seen in reverse transcriptase where a non-
polar methionine at position 189, a positively charged lysine
at position 196, and a nonpolar valine at position 251 in
EIAVUK are replaced in all EIAVPV4.9 clones by a nonpolar
valine, positively charged arginine, and nonpolar isoleucine,
respectively. Similarly, the positively charged arginine res-
idue at position 405 in EIAVUK is represented by a posi-
tively charged lysine in three of the four EIAVPV4.9 clones.
A potentially less conservative substitution is seen at
amino acid position 45 in gag p9, where a polar asparagine
residue in EIAVUK is replaced by a positively charged
histidine in all four EIAVPV4.9 clones. However, as this
substitution is located in the carboxyl terminus of the 51-
amino-acid protein it is significantly downstream from the
tyrosine (Y), proline (P), aspartic acid (D), leucine (L) late
domain (amino acid positions 23 to 26) that is indispensable
for virus particle budding (Puffer et al., 1997; Chen et al.,
2001; Li et al., 2002). Furthermore, the carboxyl terminus of
p9, including amino acid position 45, can be deleted without
complete abrogation of function (Chen et al., 2001), sug-
gesting that this domain has an ancillary or modulatory role
that may not be compromised by the substitution of certain
amino acids.
As a result of the failure to implicate differences in the
gag/pol genes, it could be inferred that pathogenicity is
attenuated by the 68-bp duplication in the 3 LTR and/or the
presence of arginine (R103) instead of tryptophan (W103) at
position 103 in ORF S3, as these are the only other variant
sequences identified between EIAVPV and EIAVUK (Cook
et al., 1998). The fact that in all the EIAVUK recipients
examined this duplication was deleted and R103 replaced by
W103 shows that there is a strong selective mechanism for
generating viral populations resembling the EIAVPV con-
sensus sequence at these locations. This consistent evolu-
tionary pressure therefore conclusively demonstrates that
the 68-bp duplication and R103 are both less than optimal for
the EIAV life cycle in vivo. Furthermore, removal of these
variant sequences from EIAVUK (EIAVUK3) increased the
incidence of acute disease in populations of E. caballus.
To account for these observations it is proposed that
EIAV burden must reach a critical or threshold level to
trigger sufficient release of pro-inflammatory cytokines
such as tumor necrosis factor-, interleukin-6, and trans-
forming growth factor- that have been implicated in the
pyrexia and thrombocytopenia associated with acute EIA
(Costa et al., 1997; Tornquist et al., 1997; Sellon et al.,
1998). Although this replication proceeds unopposed in
foals with severe combined immunodeficiency (Perryman et
al., 1988; Mealey et al., 2001), resulting in a fatal acute
disease, in normal horses/ponies it is counteracted by the
development of powerful adaptive immune responses
(McGuire et al., 1994; Hammond et al., 1997). Therefore,
the clinical outcome following infection with EIAVPV-like
viruses can be visualized as a race between viral replication
leading to high viral burdens and the establishment of initial
immunological control. In this model the replicative poten-
tial of EIAV in vivo is the primary determinant of patho-
genicity.
It is estimated, based on real-time RT–PCR data col-
lected to date (this study and R.F. Cook, unpublished), that
the threshold level for the induction of acute disease in a
majority of horses/ponies is correlated with a plasma-asso-
ciated viral RNA load of 5  107 to 1  108 copies/ml.
Comparison of the calculated average peak plasma viral
RNA level between EIAVUK (2.85  107 copies/ml) and
EIAVUK3 (1.72  108 copies/ml) infections indicates that
the presence of the 68-bp duplication and/or R103 results in
an average sixfold decrease in the maximal accumulation of
viral genetic material. Therefore the 68-bp duplication
and/or R103 are predicted to slow the rate of EIAV accu-
mulation such that in most cases, the threshold level is not
reached before the rapidly developing immune response
becomes sufficiently effective to curtail viral replication.
Furthermore, once established the immune response appar-
ently continues to restrict EIAVUK replication even though
the viral population undergoes apparent increases in biolog-
ical fitness by deleting the 68-bp duplication and replacing
R103 with W103. Under these circumstances EIAVUK could
only induce disease if the increases in biological fitness
were accompanied by antigenic changes to permit evasion
of the immune response. Those EIAVUK-infected animals
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that succumbed to acute disease appeared to represent a
minority of the horse population in which viral replication
was either less efficiently contained (suggested in the case
of 764) or febrile episodes were triggered at a lower viral
burden threshold (a possible explanation for clinical signs in
614 and 700).
The mechanisms involved in limiting peak viral RNA
accumulation by the 68-bp duplication and/or R103 remain
to be determined. Although it is located upstream from all
previously identified, cis-acting transcriptional control ele-
ments (Carvalho and Derse, 1993; Carvalho et al., 1993;
Derse et al., 1987; Maury, 1994, 1998), analysis using the
MatInspector 2.2 algorithm (Quandt et al., 1995) suggested
that the duplication could introduce new transcription factor
binding motifs with an 85.5% core sequence homology to
Tata box elements, the binding sites for interferon regula-
tory factors 1 and 2, the mouse homeobox gene S8, the
C-myb proto-oncogene, and the barbiturate inducible ele-
ment. Therefore, the presence of the duplication might re-
sult in the recruitment of additional nuclear transcription
factors that could interfere with normal viral RNA synthe-
sis. The experimental evidence showing no significant dif-
ferences in progeny virus production from MDM or FEK
cells and equivalent tat-associated CAT reporter gene tran-
scription from the EIAVUK and EIAVUK3 LTRs demon-
strates that if such interference occurs it can only be of a
very small magnitude. However, this does not exclude the
possibility of direct effects on viral transcription because
dramatic shifts in viral populations can be caused by just
small (1–2%) differences in fitness between variants (Du-
arte et al., 1994). Such differences are unlikely to be de-
tectable by simple, noncompetitive cell infectivity or CAT
reporter gene assays because of their inherent variability
and relative insensitivity. However, the CAT assay data
suggests some intriguing alternative mechanisms. In the
absence of tat the promoter activity of the EIAV LTR is
normally reduced by at least 100-fold (Dorn et al., 1990;
Noiman et al., 1990; Carroll et al., 1991; Rosin-Arbesfeld et
al., 1998). Although this reduction was confirmed with the
EIAVUK3 LTR only a fivefold decrease was observed in
tat-independent promoter activity from the 3 LTR of
EIAVUK. Therefore, the 68-bp duplication appears to con-
stitute at least in part a relatively active transcriptional unit
that is not under the normal rigorous control of tat. If this
relaxation in transcriptional control altered the pattern of
EIAV protein production, particularly in monocytes, where
viral expression is quiescent until cell differentiation is
complete (Maury, 1994), it could increase the exposure to
protective immune responses.
In addition to the 68-bp duplication, the presence of R103
in ORF S3 could also have a significant impact on the
accumulation of peak viral RNA levels in vivo. The EIAV
rev protein, of which the second exon is encoded by ORF
S3, plays a viral role in EIAV replication by facilitating the
nuclear export of unspliced genomic and singly spliced viral
RNAs (Saman et al., 1990; Rosin-Arbesfeld et al., 1993;
Martarano et al., 1994; Meyer et al, 1996). Extensive ge-
netic heterogeneity in ORF S3 exists between different
EIAV isolates (Alexanderson and Carpenter, 1991; Leroux
et al., 1997; Belshan et al., 1998) that in some cases has
been shown to affect the nuclear export activity of the rev
protein (Belshan et al., 1998; 2001). An analysis of se-
quences deposited in GenBank suggests that there is exten-
sive conservation of W103 in ORF S3 in the case of EIAV
samples isolated directly from infected horses or ponies.
However, for example, when EIAVMA-1 was subjected to
extensive growth in equine dermal cells substitution of the
W103 residue was observed in six of the seven samples
examined. In five of these samples the replacement residue
was glutamine, while the sixth resembled EIAVUK in hav-
ing arginine located at position 103 in ORF S (Belshan et
al., 1998). These results suggest that for optimal replication
in E. caballus, EIAV must possess a nonpolar tryptophan
residue at position 103 in the second exon of rev, whereas
for growth in fibroblastic cell types this requirement
switches to a polar glutamine or positively charged arginine.
The data presented in this report strongly support this con-
clusion.
In summary, EIAVUK differs from the 3 EIAVPV con-
sensus sequence by the possession of a 68-bp duplication in
the LTR and R103 instead of W103 in ORF S3. These
differences were suboptimal in vivo, being subjected to
intense selective pressure resulting in restoration of se-
quences homologous to the EIAVPV consensus at both lo-
cations. Furthermore, removal of the duplication and re-
placement of R103 with W103 produced a modified
infectious molecular clone (EIAVUK3) with an equivalent (P
 0.03) pathogenic potential to EIAVPV. The results of this
study demonstrate that ORF S3 and/or regions of the LTR
not previously associated with cis-acting transcriptional
control elements can modulate EIAV virulence. Therefore,
defined modifications in these genetic elements can be used
to determine viral replication levels and hence the pathoge-
nicity in E. caballus.
Materials and methods
PCR amplification and molecular cloning of 4.9-kbp 5
terminal fragments from the EIAVPV strain
The 4.9-kbp 5 terminal fragment of the EIAVPV strain
was amplified from 0.1 g of FEK-infected cell DNA
(Cook et al., 1998) using the oligonucleotide primers
HindIII/EIAV1 and EIAV4861 (Table 1) in conjunction with
the Expand High Fidelity PCR System (Roche Molecular
Biochemicals, Indianapolis, IN). The reactions (50 l) were
prepared as recommended by the manufacturer with 1.5 M
MgCl2 and subjected to 30 cycles of melting at 94°C for
15 s, annealing at 66°C for 30 s, with an extension at 68°C
for 8 min. Primer EIAV4861 encompassed the NcoI restric-
tion endonuclease site at position 4873 in EIAVPV (Fig. 1).
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Therefore, following digestion with HindIII plus NcoI and
purification from an agarose gel using Agar ACE (Promega,
Madison, WI) as described in the manufacturer’s recom-
mendations, the resultant 4.9-kbp fragments were ligated
into HindIII–NcoI-digested pLG338/30 plasmid DNA. This
plasmid is a low copy number vector that has been shown
(Cunningham et al., 1993) to stabilize EIAV gene sequences
during molecular cloning in Escherichia coli. Finally the
ligated products were used to transform E. coli SURE cells
(Stratagene, La Jolla, CA) and the resultant molecular
clones designated EIAVPV4.9.
Construction of EIAVUK2 and EIAVUK3 infectious
molecular clones
In EIAVUK2 the majority of its gag-pol sequences were
derived from EIAVPV, while the 3 3.3-kbp fragment re-
mained identical to that in EIAVUK. This was accomplished
(Fig. 1) by substitution of an AspI (located at nucleotide
position 643 in EIAVUK)/NcoI (located at nucleotide posi-
tion 4873 in EIAVUK) fragment from EIAVPV4.9 No. 7 into
EIAVUK.
EIAVUK3 differed from EIAVUK by the absence of the
68-bp duplication in the 3 LTR and by the possession of
tryptophan instead of arginine at amino acid position 103 in
ORF S3. It was produced by exchanging a BstX1 (located at
nucleotide position 7444 in EIAVUK)/EcoRI fragment in
EIAVUK with an equivalent region of the genome obtained
from a molecular clone that in this particular area possessed
complete homology with the EIAVPV consensus sequence
(Leroux et al., 1997).
In the above substitutions restriction endonuclease di-
gests were conducted according to the manufacturer’s rec-
ommendations (Roche Molecular Biochemicals) and all
fragments were purified by agarose gel electrophoresis fol-
lowed by extraction with Agar ACE (Promega).
Preparation and infection of equine monocyte-derived
macrophage cultures
Equine MDM cultures were prepared from EIAV-sero-
negative donors as described previously (Maury, 1994;
Raabe et al., 1998) except that aphidicolin (Sigma-Aldrich,
St. Louis, MO) at 0.5 g/ml was added to the maintenance
medium to inhibit the growth of the prefibroblastic cells that
are frequently encountered in venous blood samples from
horses. The MDMs were seeded into 48-well tissue culture
plates at 4 105 cells per well and incubated at 37°C in 6%
CO2 before being infected with viruses from EIAVUK or
EIAVUK3 (8 wells per virus strain) at a m.o.i. of 0.1 TCID50.
Viral RNA isolated using the High Pure TM Viral RNA kit
from 0.2 ml of MDM culture fluids at 6 dpi was quantitated
by real-time RT–PCR.
Transfection of cell cultures with infectious molecular
clones of EIAV
Plasmid DNA preparations of EIAVUK2 and EIAVUK3
were purified using a Midiprep kit (Qiagen Inc., Santa
Clara, CA). These purified preparations (4 g) were trans-
fected into FEK cell cultures (at 2  105 cells per 35-mm
diameter well) by using a polycationic lipid transfection
reagent (Lipofectamine; Gibco Life Technologies, Gaithers-
burg, MD) according to the manufacturer’s instructions.
After a 21- to 24-day incubation period (which included
passage and amplification of the cell numbers), tissue cul-
ture fluids from transfected cell cultures were screened for
released reverse transcriptase activity (Cook et al., 1992),
aliquoted, and stored at 70°C until further use. The titers
of the chimeric virus stocks were determined by performing
serial log10 dilutions in modified Eagle’s medium contain-
ing 3% fetal bovine serum, 25 mM HEPES, 10 mM
NaHCO3, 100 IU of penicillin/ml, and 100 g of strepto-
mycin/ml and inoculating each dilution onto fresh FEK cell
cultures. These FEK cell cultures were monitored for 21
days, after which the culture fluids were assayed for reverse
transcriptase activity (Cook et al., 1992) and the titration
endpoint was determined by the Karber method (Dougherty,
1964).
LTR CAT reporter gene assay
Complete copies of the 3 EIAVUK and EIAVUK3 LTRs
were generated by PCR using the HindIII EIAV1–XbaI
EIAV8283 oligonucleotide primer pair (Table 1) on DNA
templates consisting of 3 3.3-kbp (NcoI/EcoRI) molecu-
larly cloned fragments of the relevant proviral genomes.
Reactions were conducted using the Expand High Fidelity
PCR System (Roche), with 30 cycles of melting at 94°C for
20 s, annealing at 66°C for 30 s, and extension at 68°C for
60 s. The HindIII and XbaI sites in the oligonucleotide
primers enabled directional ligation of the resultant PCR
fragments into the pCAT-Basic plasmid vector (Promega).
Ligation products were used to transform E. coli SCS110
(dam) cells (Stratagene) and four of each resultant EIAVUK
and EIAVUK3 LTR clone (pUKLTR-CAT, pUK3LTR-
CAT) were subjected to nucleotide sequence analysis to
ensure that mutations had not been introduced into the LTR
during the amplification or molecular cloning procedures.
The pUKLTR-CAT and pUK3LTR-CAT constructs (3 g)
were transfected in triplicate as described above into ED
(obtained from the American Type Culture Collection-
ATCC CCL-57) cell cultures in conjunction with 1 g of
the EIAV tat protein expression vector pRS-ETAT-M
(kindly donated by Dr. David Derse, National Cancer Insti-
tute, Frederick, MA) or 1 g of pCI (Promega) control
vector. Transfected ED cells were incubated for 40 h at
37°C in 5% CO2 prior to analysis of CAT expression using
a CAT ELISA kit (Roche) on 250 g of cell lysate.
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Detection of the 68-bp duplication in viral RNA from
plasma samples isolated from EIAVUK-infected animals
Plasma samples (2 ml) harvested at various times fol-
lowing infection with EIAVUK were centrifuged at 37,100 g
for 2 h at 4°C. The resultant pellets were resuspended in 200
l of diethyl pyrocarbonate (DEPC)-treated H2O and RNA
extracted using the High Pure Viral RNA kit (Roche Mo-
lecular Biochemicals) as directed by the manufacturer. After
elution from the High Pure matrix material the nucleic acids
were ethanol precipitated in the presence of 3.75 M ammo-
nium acetate. Precipitated nucleic acids were washed once
in 70% ethanol, allowed to air dry, and resuspended in 5 l
of DEPC-treated H2O containing 4 units of RNasin (Pro-
mega). These RNA samples were subjected to analysis by
RT–PCR using a pair of oligonucleotide primers which
spanned the U3 region of the LTR. The 5 primer
(EIAV7812, Table 1) was located within the coding se-
quences for the transmembrane glycoprotein at nucleotide
position 7812 in the EIAVUK molecular clone (Cook et al.,
1998), while the 3 primer (EIAV8179, Table 1) was located
within the R region of the LTR at position 8179. With an
EIAVUK viral preparation these primers would be predicted
to produce a 398-bp product, whereas viruses containing an
LTR of normal size would give rise to a 330-bp fragment.
Reverse transcription reactions were performed using 2.0 l
of RNA sample in 50 mM KCl, 10 mM Tris–HCl, pH 8.3,
4.5 mM MgCl2, 1 mM each dNTP, 1 unit/l of RNase
inhibitor, 20 pmol of the EIAV8179 primer, and 2.5 units/l
of Moloney murine leukemia virus reverse transcriptase
(Applied Biosystems, Foster City, CA). Each reaction was
adjusted to a final volume of 20 l, overlaid with mineral
oil, and incubated at 42°C for 45 min before being heated to
99°C for 5 min. Following reverse transcription, the con-
centration of the reaction mixture was adjusted to 2 mM
MgCl2, 50 mM KCl, 10 mM Tris–HCl, pH 8.3, 20 pmol of
the EIAV7812 primer, and 2.5 units of AmpliTaq DNA
polymerase (Applied Biosystems) in a final volume of 100
l. These reaction mixtures were subjected to 5 cycles of
melting at 95°C for 20 s, annealing at 54°C for 30 s, and
extension at 72°C for 60 s. This was followed by 30 cycles
of melting at 95°C for 20 s, annealing at 50°C for 30 s, and
extension at 72°C for 60 s. The products of these reactions
were analyzed by electrophoresis in 1.2% agarose gels and
visualized by ethidium bromide staining.
Molecular cloning of RT–PCR products derived using the
EIAV7812/8179 oligonucleotide primer pair
Following RT–PCR using the EIAV7812/8179 oligonucle-
otide primer pair products detected at 8 and 12 dpi from four
of the EIAVUK-infected animals described above were iso-
lated from 1.2% low-melting-point agarose gels by diges-
tion with AgarAce (Promega) according to the manufactur-
er’s recommendations. Following purification each
fragment was molecularly cloned into the pT7 Blue-3 vector
using the Perfectly Blunt cloning kit (Novagen, Inc., Mad-
ison, WI). Five molecular clones were selected of each
fragment at both time points from all four animals. Plasmid
DNA was prepared from each molecular clone using a
Qiagen Miniprep (Qiagen) and the nucleotide sequence de-
termined in both directions using the oligonucleotide prim-
ers EIAV7812 and EIAV8179.
Identification of the amino acid residue at position 103 in
ORF S3 in EIAVUK-infected animals
Viral RNA was prepared from plasma samples collected
at various times postinfection with EIAVUK as outlined
above. This viral RNA was subjected to reverse transcrip-
tion using the EIAV8179 oligonucleotide primer as described
for the analysis of the 68-bp duplication. The resultant
cDNA was amplified by PCR, again as outlined above for
the analysis of the 68-bp duplication, except that 20 pmol of
the EIAV7034 oligonucleotide primer (Table 1) was added to
the reaction mixture. These reaction mixtures were sub-
jected to 5 cycles of melting at 95°C for 20 s, annealing at
56°C for 30 s, and extension at 72°C for 2 min. This was
followed by 30 cycles of melting at 95°C for 20 s, annealing
at 51°C for 30 s, and extension at 72°C for 2 min. The
resultant PCR products were isolated from 1.2% low-melt-
ing-point agarose gels by digestion with AgarAce and mo-
lecularly cloned into the pT7 Blue-3 vector using the Per-
fectly Blunt cloning kit. These molecular clones were
sequenced using overlapping EIAV primers (Leroux et al.,
1997).
Nucleotide sequencing
Plasmid DNA was extracted and purified with Miniprep
or Midiprep kits (Qiagen). This purified DNA was se-
quenced using a Thermo Sequenase Cy 5.5 dye terminator
cycle sequencing kit (Amersham Pharmacia Biotech, Pisca-
taway, NJ) using overlapping EIAV primers derived from
published sequences (Cook et al., 1998; Leroux et al., 1997;
Stephens et al., 1986). The sequences were resolved using
an OpenGene automated DNA sequencing system (Visible
Genetics Inc., Toronto, Ontario, Canada).
Experimental subjects
The ponies (662, 839, 873, and 930) were of mixed breed
origin, while the majority of the horses (1, 6, 9, 10, 985, and
986) were Thoroughbreds. The ages of these animals ranged
from 2 to 20 years. Before inclusion in an experiment the
animals were tested and found negative for antibodies
against EIAV using tests approved by the United States
Department of Agriculture. The animals were housed in
screened box stalls to exclude hematophagous insects and
all handling protocols pertaining to them received prior
approval from the University of Kentucky Institutional An-
imal Care and Use Committee. The horses and ponies were
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treated with Ivermectin for internal parasites and vaccinated
against tetanus toxoid (Merck, Sharp & Dohme, Rahway,
NJ). Animals were inoculated intravenously, using clarified
(3000 g for 30 min at 4°C) cell culture fluids from
EIAVUK-, EIAVUK1-, EIAVUK2-, EIAVUK3-, or EIAVUK4-
transfected cell cultures at 4  106 50% tissue culture
infective doses (TCID50). All animals were monitored on a
daily basis for rectal temperature and overall clinical status.
Blood samples were collected at regular intervals by jugular
venipuncture into sterile glass evacuated tubes (Becton–
Dickinson, Rutherford, NJ) for serum or with EDTA for
plasma (Sherwood Medical, St. Louis, MO). Serum and
plasma were stored at 20 and 70°C, respectively. In
addition, fresh blood samples collected in the presence of
EDTA were analyzed to determine platelet numbers using
the Idexx QBC VetAutoread hematology system (Idexx
Laboratories, Inc., Westbook, ME). Platelet numbers were
determined at least weekly and during each febrile episode
(39.0°C). Virus isolation from plasma samples on FEK
cell cultures was as described previously (Issel et al., 1992;
Wang et al., 1994) and determination of viral titers in these
samples was conducted by inoculation of serial log10 dilu-
tions onto FEK cells. All cultures were maintained for at
least 21 days, after which they were assayed for reverse
transcriptase activity (Cook et al., 1992). Serum samples
were tested for antibodies against EIAV using tests ap-
proved by the United States Department of Agriculture,
including agar gel immunodiffusion (EIA-AGID, Idexx
Laboratories, Inc.) and enzyme-linked immunosorbent as-
say systems (EIA-CELISA, Idexx Laboratories Inc., VI-
RACHEK/EIA, Synbiotics Corp., San Diego, CA, SA-
ELISAII, Viral Antigens, Inc., Memphis, TN).
Real-time RT–PCR quantitation of EIAV RNA from
plasma samples
A single-tube RT–PCR using a fluorogenic real-time
PCR detection method for the quantitation of EIAV gag
gene containing RNA has been described previously (Cook
et al., 2002). To compensate for variations inherent in sam-
ple preparation this utilizes a multiplex procedure in which
plasma samples are seeded with 108 copies of a green
fluorescent protein (gfp) RNA transcript (Klein et al., 2001).
The use of separate gfp-specific primers and a fluorogenic
probe permits the simultaneous calculation of nucleic acid
recovery rate along with the copy number of EIAV RNA
molecules (Cook et al., 2002).
Each 25-l RT–PCR mixture contained 1  EZ buffer
(Applied Biosystems, Foster City, CA, 50 mM bicine, 115
mM potassium acetate, 8% wt/vol glycerol, pH 8.2), 300
M each dNTP, 2.5 mM manganese acetate, 200 nM EIAV
1572F, 200 nM EIAV 1769R, 125 nM EIAV probe, 40 nM
GFP F, 40 nM GFPR, 125 nM GFP probe, 40 units of
RNasin, and 2.5 units of rTth (Applied Biosystems). Re-
verse transcription and amplification were performed using
the Smart Cycler real time thermal cycler (Cepheid, Sunny-
vale, CA). To prevent binding of nuclei acids and poly-
merases to the reaction tubes, Cepheid recommends the
addition of an “Additive Reagent.” Therefore, this reagent
was added to each reaction, giving a final concentration of
0.2 mg/ml of bovine serum albumin (nonacetylated), 0.15
M trehalose, and 0.2% Tween 20.
The analysis of data was performed with version 1.2b
Smart Cycler Software using the preset default values of the
Primary Curve Analysis. Standard curves were produced by
preparing log10 dilutions of an in vitro synthesized (Cook et
al., 2002) EIAV gag gene RNA transcript (with each dilu-
tion seeded with 108 molecules of gfp transcript) and ana-
lyzed by plotting the cycle number versus the fluorescent
signal. A sample was deemed positive once the fluorescence
signal exceeded the preset default value of 30 fluorescent
units. The cycle number at which this occurred was defined
as the cycle threshold.
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